Cognitive impairment is common following traumatic brain injury (TBI), and neuroinflammatory mechanisms may predispose to the development of neurodegenerative disease. Apolipoprotein E (apoE) polymorphisms modify neuroinflammatory responses, and influence both outcome from acute brain injury and the risk of developing neurodegenerative disease. We demonstrate that TBI accelerates neurodegenerative pathology in double-transgenic animals expressing the common human apoE alleles and mutated amyloid precursor protein, and that pathology is exacerbated in the presence of the apoE4 allele. The administration of an apoE-mimetic peptide markedly reduced the development of neurodegenerative pathology in mice homozygous for apoE3 as well as apoE3/E4 heterozygotes. These results demonstrate that TBI accelerates the cardinal neuropathological features of neurodegenerative disease, and establishes the potential for apoE mimetic therapies in reducing pathology associated with neurodegeneration.
Get full access to this article
View all access options for this article.
References
1.
BargerS.W., HarmonA.D.1997. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature, 388:878–881.
2.
BruggB., DubreuilY.L., HuberG., WollmanE.E., Delhaye-BouchaudN., MarianiJ.1995. Inflammatory processes induce beta-amyloid precursor protein changes in mouse brain. Proc. Natl. Acad. Sci. USA, 92:3032–3035.
3.
BueeL., BussiereT., Buee-ScherrerV., DelacourteA., HofP.R.2000. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev., 33:95–130.
4.
CarrollL.J., CassidyJ.D., PelosoP.M., BorgJ., von HolstH.et al.2004. Prognosis for mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J. Rehabil. Med., 43,Suppl.:84–105.
5.
CorderE.H., SaundersA.M., StrittmatterW.J., SchmechelD.E., GaskellP.C.et al.1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 261:921–923.
6.
CorrealeJ., VillaA.2004. The neuroprotective role of inflammation in nervous system injuries. J. Neurol., 251:1304–1316.
7.
DawsonH.N., CantillanaV., ChenL., VitekM.P.2007. The tau N279K exon 10 splicing mutation recapitulates frontotemporal dementia and parkinsonism linked to chromosome 17 tauopathy in a mouse model. J. Neurosci., 27:9155–9168.
8.
DawsonH.N., CantillanaV., JansenM., WangH., VitekM.P.et al.2010. Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease. Neurosciencein press.
9.
FaganA.M., WatsonM., ParsadanianM., BalesK.R., PaulS.M., HoltzmanD.M.2002. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis., 9:305–318.
10.
GalloG., WisniewskiT., Choi-MiuraN.H., GhisoJ., FrangioneB.1994. Potential role of apolipoprotein-E in fibrillogenesis. Am. J. Pathol., 145:526–530.
GaoJ., WangH., ShengH., LynchJ.R., WarnerD.S.et al.2006. A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage. Neurocrit. Care, 4:25–31.
13.
Gomez-RamosP., Asuncion MoranM.2007. Ultrastructural localization of intraneuronal Abeta-peptide in Alzheimer disease brains. J. Alzheimers Dis., 11:53–59.
14.
GuoZ., CupplesL.A., KurzA., AuerbachS.H., VolicerL.et al.2000. Head injury and the risk of AD in the MIRAGE study. Neurology, 54:1316–1323.
15.
HerzJ., BeffertU.2000. Apolipoprotein E receptors: linking brain development and Alzheimer's disease. Nat. Rev. Neurosci., 1:51–58.
16.
HoaneM.R., PierceJ.L., HollandM.A., BirkyN.D., DangT.et al.2007. The novel apolipoprotein E-based peptide COG1410 improves sensorimotor performance and reduces injury magnitude following cortical contusion injury. J. Neurotrauma, 24:1108–1118.
17.
HoeH.S., HarrisD.C., RebeckG.W.2005. Multiple pathways of apolipoprotein E signaling in primary neurons. J. Neurochem., 93:145–155.
18.
HoltzmanD.M., BalesK.R., TenkovaT., FaganA.M., ParsadanianM.et al.2000. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 97:2892–2897.
19.
HoofienD., GilboaA., VakilE., DonovickP.J.2001. Traumatic brain injury (TBI) 10-20 years later: a comprehensive outcome study of psychiatric symptomatology, cognitive abilities and psychosocial functioning. Brain Inj., 15:189–209.
20.
IkonomovicM.D., UryuK., AbrahamsonE.E., CiallellaJ.R., TrojanowskiJ.Q.et al.2004. Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp. Neurol., 190:192–203.
21.
KaufmanN.A., BeareJ.E., TanA.A., VitekM.P., McKennaS.E., HoaneM.R.2010. COG1410, an apolipoprotein E-based peptide, improves cognitive performance and reduces cortical loss following moderate fluid percussion injury in the rat. Behav. Brain Res., 214:395–401.
22.
KelleyB.J., LifshitzJ., PovlishockJ.T.2007. Neuroinflammatory responses after experimental diffuse traumatic brain injury. J. Neuropathol. Exp. Neurol., 66:989–1001.
LaskowitzD.T., VitekM.P.2007. Apolipoprotein E and neurological disease: therapeutic potential and pharmacogenomic interactions. Pharmacogenomics, 8:959–969.
LaskowitzD.T., GoelS., BennettE.R., MatthewW.D.1997. Apolipoprotein E suppresses glial cell secretion of TNF alpha. J. Neuroimmunol., 76:70–74.
27.
LaskowitzD.T., McKennaS.E., SongP., WangH., DurhamL.et al.2007. COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. J. Neurotrauma, 24:1093–1107.
28.
LaskowitzD.T., ThekdiA.D., ThekdiS.D., HanS.K., MyersJ.K.et al.2001. Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp. Neurol., 167:74–85.
29.
LiF.Q., SempowskiG.D., McKennaS.E., LaskowitzD.T., ColtonC.A., VitekM.P.2006. Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis. J. Pharmacol. Exp. Ther., 318:956–965.
30.
LintonM.F., GishR., HublS.T., ButlerE., EsquivelC.et al.1991. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J. Clin. Invest., 88:270–281.
31.
LivakK.J., SchmittgenT.D.2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 25:402–408.
32.
LynchJ.R., TangW., WangH., VitekM.P., BennettE.R.et al.2003. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J. Biol. Chem., 278:48529–48533.
33.
LynchJ.R., WangH., MaceB., LeinenweberS., WarnerD.S.et al.2005. A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. Exp. Neurol., 192:109–116.
34.
MayeuxR., OttmanR., MaestreG., NgaiC., TangM.X.et al.1995. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology, 45:555–557.
35.
MesisR.G., WangH., LombardF.W., YatesR., VitekM.P.et al.2006. Dissociation between vasospasm and functional improvement in a murine model of subarachnoid hemorrhage. Neurosurg. Focus, 21:E4.
36.
MisraV., MisraS.P., HatwalD., DwivediM., SinghK.G., BajajA.K.2001. Helicobacter pylori and associated histopathological changes in gastric biopsies of patients with leprosy. Indian J. Pathol. Microbiol., 44:271–275.
37.
NicollJ.A., RobertsG.W., GrahamD.I.1995. Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat. Med., 1:135–137.
38.
OphirG., AmariglioN., Jacob-HirschJ., ElkonR., RechaviG., MichaelsonD.M.2005. Apolipoprotein E4 enhances brain inflammation by modulation of the NF-kappaB signaling cascade. Neurobiol. Dis., 20:709–718.
39.
PlassmanB.L., HavlikR.J., SteffensD.C., HelmsM.J., NewmanT.N.et al.2000. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology, 55:1158–1166.
40.
RobertsG.W., GentlemanS.M., LynchA., MurrayL., LandonM., GrahamD.I.1994. Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry, 57:419–425.
41.
SadowskiM.J., PankiewiczJ., ScholtzovaH., MehtaP.D., PrelliF.et al.2006. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 103:18787–18792.
42.
SallowayS., SperlingR., GilmanS., FoxN.C., BlennowK.et al.2009. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology, 73:2061–2070.
43.
SchmechelD.E., SaundersA.M., StrittmatterW.J., CrainB.J., HuletteC.M.et al.1993. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA, 90:9649–9653.
SullivanP.M., MaceB.E., MaedaN., SchmechelD.E.2004. Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. Neuroscience, 124:725–733.
46.
SullivanP.M., MezdourH., ArataniY., KnouffC., NajibJ.et al.1997. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J. Biol. Chem., 272:17972–17980.
47.
SzekelyC.A., BreitnerJ.C., FitzpatrickA.L., ReaT.D., PsatyB.M., KullerL.H., ZandiP.P.2008. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology, 70:17–24.
48.
TangM.X., MaestreG., TsaiW.Y., LiuX.H., FengL.et al.1996. Effect of age, ethnicity, and head injury on the association between APOE genotypes and Alzheimer's disease. Ann. NY Acad. Sci., 802:6–15.
49.
UryuK., ChenX.H., MartinezD., BrowneK.D., JohnsonV.E.et al.2007. Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp. Neurol., 208:185–192.
50.
UryuK., LaurerH., McIntoshT., PraticoD., MartinezD.et al.2002. Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J. Neurosci., 22:446–454.
51.
VitekM.P., BrownC.M., ColtonC.A.2009. APOE genotype-specific differences in the innate immune response. Neurobiol. Aging, 30:1350–1360.
52.
WangH., GaoJ., LassiterT.F., McDonaghD.L., ShengH.et al.2006. Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocrit. Care, 5:71–78.
53.
WangH., LynchJ.R., SongP., YangH.J., YatesR.B.et al.2007. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp. Neurol., 206:59–69.
54.
WilcockD.M., GordonM.N., MorganD.2006. Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat. Protoc., 1:1591–1595.
55.
WirthsO., BreyhanH., SchaferS., RothC., BayerT.A.2008. Deficits in working memory and motor performance in the APP/PS1ki mouse model for Alzheimer's disease. Neurobiol. Aging, 29:891–901.
56.
WirthsO., MulthaupG., BayerT.A.2004. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide—the first step of a fatal cascade. J. Neurochem., 91:513–520.
57.
ZhouW., XuD., PengX., ZhangQ., JiaJ., CrutcherK.A.2008. Meta-analysis of APOE4 allele and outcome after traumatic brain injury. J. Neurotrauma, 25:279–290.
